** Shares of drug developer Kymera Therapeutics KYMR.O rise 7.8% to $107.8 premarket

** Co says it has completed enrollment for the mid-stage trial of its experimental treatment, KT-621, to treat moderate to severe atopic dermatitis

** Enrollment finished earlier than expected, allowing Kymera to bring forward its topline data to year-end 2026 - six months ahead of the previous mid-2027 guidance - KYMR

** Co says it expects to begin late-stage trials by mid-2027

** RBC Capital Markets says "accelerated timelines should move KYMR back onto investors' 2026 radars, and we continue to see strong prospects for 621 and upside potential for shares"

** "This speaks to the level of excitement investigators and patients have towards this new mechanism of action and an oral alternative to Regeneron's Dupixent" - J.P.Morgan

** As of last close, stock up 28.4% YTD